The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females

Lipids in Health and Disease

Michel F Rousseau¹  Sylvie A Ahn¹  Michel P Hermans² 

[1] Division of Cardiology, Université catholique de Louvain, Brussels, Belgium;Division of Endocrinology and Nutrition, Université catholique de Louvain, Brussels, Belgium

关键词: Diabetes;    Gender;    Hyperbolic product;    β-cell function;    Microangiopathy;    Cardiovascular risk;    Triglycerides;    HDL-C;   

Others  :  1160183
DOI  :  10.1186/1476-511X-11-132

 received in 2012-04-26, accepted in 2012-09-30,  发布年份 2012

【 摘 要 】

Background

Atherogenic dyslipidemia (AD), defined as low HDL-C plus elevated triglycerides (TG), comorbid to T2DM, increases cardiometabolic risk for CAD even when LDL-C is at target. In T2DM males, AD was shown to correlate with β-cell function loss, yet it is not established whether this applies across gender.

Aim

To establish the prevalence and severity of AD in T2DM females, and to determine how it relates to cardiometabolic phenotype, glucose homeostasis, micro- and macrovascular complications, and 10-year absolute CV risk (UKPDS Risk Engine).

Methods

340 T2DM females were ranked according to quintiles (Q) of the continuous variable log(TG)/HDL-C, with AD prevalence defined as HDL-C <50 mg.dL^-1 plus TG ≥150 mg.dL^-1, and β-cell function assessed with HOMA.

Results

AD prevalence was 35%; mean HDL-C and TG were 52 (15) and 160 (105) mg.dL^-1. AD was significantly related to central fat, metabolic syndrome, sedentarity and skeletal sarcopenia, as well as to _hsCRP, fibrinogen, uric acid, cystatin-C, Big ET-1, and 10-year UKPDS CV risk. AD correlated stepwise with lower β-cell function and hyperbolic product, and with accelerated loss of residual insulin secretion, higher HbA_1c and prevalent microangiopathy.

Conclusions

log(TG)/HDL-C is a simple means to grade AD and residual macrovascular risk in T2DM females. This ratio associates with major non-LDL cardiometabolic variables and ranks predicted CAD risk. In addition, log(TG)/HDL-C identifies worsening glucose homeostasis, poorer glycemic control, and prevalent microangiopathy.

【 授权许可】

   
2012 Hermans et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]American Diabetes Association: Standards of medical care in diabetes - 2009. Diabetes Care 2009, 32:S13-S61.
• [2]Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL: Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008, 51:1512-1524.
• [3]Fruchart J-C, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche J-M, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P for the Residual Risk Reduction Initiative: The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008, 102:1-34.
• [4]Hermans MP, Fruchart JC: Reducing residual vascular risk in patients with atherogenic dyslipidaemia: where do we go from here? Clinical Lipidology 2010, 5:811-826.
• [5]Hermans MP, Ahn SA, Rousseau MF: Residual vascular risk in T2DM: the next frontier. In Recent Advances in the Pathogenesis, Prevention and Management of Type 2 Diabetes and its Complications. Rijeka (Croatia): Intech; 2011.
• [6]Davignon J, Cohn JS: Triglycerides: a risk factor for coronary heart disease. Atherosclerosis 1996, 124(Suppl):S57-S64.
• [7]Hermans MP, Ahn SA, Rousseau MF: Log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males. Cardiovasc Diabetol 2010, 9:88. BioMed Central Full Text
• [8]Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J: Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-1639.
• [9]Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP, ACCORD Study Group: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574.
• [10]Fruchart J-C, Sacks FM, Hermans MP: Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R3i). Curr Med Res Opin 2010, 26:1793-1797.
• [11]Hermans MP: Prevention of microvascular diabetic complications by fenofibrate: Lessons from FIELD and ACCORD. Diab Vasc Dis Res 2011, 8:180-189.
• [12]Singh R, Wiegers SE, Goldstein BJ: Impact of gender on diabetes mellitus and its associated cardiovascular risk factors. J Gend Specif Med 2001, 4:28-36.
• [13]Mosca L, Appel LJ, Benjamin EJ, American Heart Association, American College of Cardiology, American College of Nurse Practitioners, American College of Obstetricians and Gynecologists, American College of Physicians, American Medical Women’s Association, Association of Black Cardiologists, Centers for Disease Control and Prevention, National Heart, Lung, and Blood Institute, National Institutes of Health, Office of Research on Women’s Health, Society of Thoracic Surgeons and World Heart Federation, et al.: Evidence-based guidelines for cardiovascular disease prevention in women. J Am Coll Cardiol 2004, 43:900-921.
• [14]Legato MJ, Gelzer A, Goland R, Ebner SA, Rajan S, Villagra V, Kosowski M: Writing Group for The Partnership for Gender-Specific Medicine. Gender-specific care of the patient with diabetes: review and recommendations. Gend Med 2006, 3:131-158.
• [15]Hermans MP, Ahn S, Rousseau MF: Neurohormonal biomarkers and UKPDS stroke risk in type 2 diabetic women on primary cardiovascular prevention. Diabetes Metab Syndr Clin Res Rev 2008, 2:93-98.
• [16]Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR: UKPDS 66: risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes. Diabetes Care 2004, 27:201-207.
• [17]Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr: International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
• [18]Sadikot S, Hermans MP: Here we go again … The metabolic syndrome revisited! Diab Metab Syndr 2010, 4:111-120.
• [19]Valdez R, Seidell JC, Ahn YI, Weiss KM: A new index of abdominal adiposity as an indicator of risk for cardiovascular disease: a cross-population study. Int J Obes 1992, 16:77-82.
• [20]Kyle UG, Morabia A, Schutz Y, Pichard C: Sedentarism affects body fat mass index and fat-free mass index in adults aged 18 to 98 years. Nutrition 2004, 20:255-260.
• [21]Burkhauser RV, Cawley J: Beyond BMI: the value of more accurate measures of fatness and obesity in social science research. J Health Econ 2008, 27:519-529.
• [22]Dehout F, Haumont S, Gaham N, Amoussou-Guenou KD, Hermans MP: Metabolic syndrome in Bantu subjects with type 2 diabetes from sub-Saharan extraction: prevalence, gender differences and HOMA-hyperbolic product. Diab Metab Syndr 2008, 2:5-11.
• [23]Munoko T, Hermans MP: Phenotypic characterization of first generation Maghrebian migrants with type 2 diabetes: a gender-based comparison with a reference North-Caucasian Belgian cohort. Diab Met Syndr 2008, 2:115-124.
• [24]Hermans MP, Ahn SA, Rousseau MF: Cardiometabolic phenotype and UKPDS risk in male type 2 diabetic patients with obstructive sleep apnoea syndrome. Diabetes Metab Syndr 2009, 3:50-54.
• [25]Hermans MP, Ahn SA, Rousseau MF: Micro- and macrovascular risk and complications in T2DM males with obstructive sleep apnoea. J Clin Metab Diab 2011, 2:64-70.
• [26]Levy JC, Matthews DR, Hermans MP: Correct Homeostasis Model Assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998, 21:2191-2192.
• [27]Hermans MP, Levy J, Morris RJ, Turner RC: Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 1999, 42:678-687.
• [28]Hermans MP, Levy J, Morris RJ, Turner RC: Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes. Diabetes 1999, 48:1779-1786.
• [29]Hermans MP: Diabetic macro- and microvascular disease in type 2 diabetes. Diabetes Vasc Dis Res 2007, 4:S7-S11.
• [30]Hermans MP, Ahn SA, Rousseau MF: Statin therapy and cataract in Type 2 diabetes. Diabetes Metab 2011, 37:139-143.
• [31]Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
• [32]Hermans MP, Ahn SA, Gruson D, Rousseau MF: The metabolic syndrome phenotype is associated with raised circulating Big endothelin-1 independently of coronary artery disease in type 2 diabetes. Diab Metab Syndr 2007, 1:229-237.
• [33]Dobiásová M, Frohlich J: The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FERHDL). Clin Biochem 2001, 34:583-588.
• [34]Hermans MP, Ahn SA, Rousseau MF: The non-HDL-C/HDL-C ratio provides cardiovascular risk stratification similar to the ApoB/ApoA1 ratio in diabetics: comparison with reference lipid markers. Diab Metab Syndr 2007, 1:23-28.
• [35]da Luz PL, Favarato D, Faria-Neto JR Jr, Lemos P, Chagas AC: High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics (Sao Paulo) 2008, 63:427-432.
• [36]Kannel WB, Vasan RS, Keyes MJ, Sullivan LM, Robins SJ: Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort). Am J Cardiol 2008, 101:497-501.
• [37]Bittner V, Johnson BD, Zineh I, Rogers WJ, Vido D, Marroquin OC, Bairey-Merz CN, Sopko G: The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women’s Ischemia Syndrome Evaluation (WISE). Am Heart J 2009, 157:548-555.
• [38]Cordero A, Andrés E, Ordoñez B, León M, Laclaustra M, Grima A, Luengo E, Moreno J, Bes M, Pascual I, Civeira F, Pocoví M, Alegría E, Casasnovas JA, MESYAS (MEtabolic Syndrome Active Subjects) Study Investigators: Usefulness of triglycerides-to-high-density lipoprotein cholesterol ratio for predicting the first coronary event in men. Am J Cardiol 2009, 104:1393-1397.
• [39]Kim-Dorner SJ, Deuster PA, Zeno SA, Remaley AT, Poth M: Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance? Metabolism 2010, 59:299-304.
• [40]Hermans MP, Sacks F, Ahn SA, Rousseau MF: Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence. Cardiovasc Diabetol 2011, 10:20. BioMed Central Full Text
• [41]Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR: Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 1998, 15:290-296.
• [42]Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281:2005-2012.
• [43]Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, Mueller M, Horváth T, Doerries C, Heinemann M, Flemmer S, Markowski A, Manes C, Bahr MJ, Haller H, von Eckardstein A, Drexler H, Landmesser U: Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010, 121:110-122.
• [44]Li C, Ford ES, Meng YX, Mokdad AH, Reaven GM: Does the association of the triglyceride to high-density lipoprotein cholesterol ratio with fasting serum insulin differ by race/ethnicity? Cardiovasc Diabetol 2008, 7:4. BioMed Central Full Text
• [45]Hermans MP, Fruchart JC: Reducing vascular events risk in patients with dyslipidemia: an update for clinicians. Ther Adv Chronic Dis 2011, 2:307-323.